In this journal club, we will discuss two pivotal studies in ILD, the FIBRONEER study and the RECITAL study:
Nerandomilast in Patients with Progressive Pulmonary Fibrosis, Maher, T.M. et al. NEJM. 2025 May 19. doi: 10.1056
Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial, Maher T.M., et al. Lancet 2023 Jan;11(1). doi: 10.1016
Panelists:
Toby Maher, MD
Shervin Assassi, MD
Jack Cush, Moderator